Skip to main content
OpenTrials
Completed

NCT Number: NCT05472324

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

This is a phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of TQC2731 on Annualized Asthma Exacerbation Rates(AAER) in adult subjects with poor control of severe asthma. It is estimated that 220 subjects will be included. The subjects will receive TQC2731 (70 mg Q4w, 210 mg Q4w, 420 mg Q4w) or placebo (Q4w) administered by Subcutaneous (SC) in the ratio of 1:1:1:1.

The study comprised a 5 to 6-week screening period, a 52-week treatment period and a 12-week follow-up period. During the treatment period, the study drug will be administered from day 0 until week 48. The study drug was not administered at the 52nd week.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GUANGZHOU FIRST PEOPLE's HOSPITAL, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1 Age. 18-75
  • 2 Documented physician-diagnosed asthma for at least 12 months before visit 1.
  • 3 Subjects who have received a physician-prescribed asthma controller medication with medium or high dose inhaled glucocorticosteroid (ICS) for at least 12 months before visit 1.
  • 4 Documented treatment with a total daily dose of either medium or high dose ICS for at least 3 months before visit 1.
  • 5 At least one additional maintenance asthma controller medication such as Long acting β2 receptor agonist (LABA), leukotriene receptor antagonist (LTRA), theophylline, Long-acting muscarinic antagonists (LAMA), sodium cromoglycate, etc. is required according to standard practice of care and must be documented for at least 3 months.
  • 6 Morning pre-BD FEV1 <80% predicted normal At visit 2 or visit 2a.
  • 7 Evidence of asthma as documented by either: Documented historical reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months before visit 1 OR Post-BD (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL during screening At visit 2 or visit 2a.
  • 8 Documented history of at least 2 asthma exacerbation events within 12 months before visit 1.
  • 9 ACQ-6 score ≥1.5 at visit 1
  • 10 Body weight ≥ 40 kg at visit 1.

Exclusion criteria

  • 1 Pulmonary disease other than asthma.
  • 2 History of cancer.
  • 3 Current smokers or subjects with smoking history ≥10 pack-years.
  • 4 Hepatitis B, C, human immunodeficiency virus (HIV) or Syphilis.
  • 5 History of anaphylaxis following any biologic therapy.
  • 6 History of chronic alcohol or drug abuse within 12 months.
  • 7 History of a clinically significant infection.
  • 8 Pregnant or breastfeeding.

Treatment and study plan

TQC2731 injection

Drug

TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

Placebo

Drug

The drug is a placebo Comparator.

Primary outcomes

  1. Annual Asthma Exacerbation Rate

    Time frame: Baseline up to Study Week 64

    The annual exacerbation rate is based on annualized asthma exacerbation rates reported by the investigator in the electronic case report form(eCRF). The analysis is based on the primary population (Full Analysis Set)

Secondary outcomes

  1. Change from baseline in forced expiratory volume in first second(FEV1) of Pre-dose and Pre-bronchodilator (Pre-BD).

    Time frame: Baseline up to Study Week 64

    FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

  2. Mean Change From Baseline in Weekly Rescue Medication Use

    Time frame: Baseline up to Study Week 64

    Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of daytime inhaler puffs + 2 x [number of day nebulizer times]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.

  3. Change From Baseline in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb) .

    Time frame: Baseline up to Study Week 64

    Mean change from baseline in FeNO (Ppb)

  4. Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ(S)+12) Total Score

    Time frame: Baseline up to Study Week 64

    The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

  5. Change From Baseline in Asthma Control Questionnaire-6(ACQ-6)

    Time frame: Baseline up to Study Week 64

    The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

  6. Mean Change From Baseline in Asthma Symptom Diary

    Time frame: Baseline up to Study Week 52

    Mean change from baseline at Week 52 in Asthma Symptom Diary (ASD). The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.

  7. Change From Baseline in 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L) VAS

    Time frame: Baseline up to Study Week 64

    Mean change from baseline in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state. EQ-5D-5L VAS.

  8. Time to First Asthma Exacerbation

    Time frame: Baseline up to Study Week 64

    Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF.

  9. Proportion of subjects with at least one asthma exacerbation

    Time frame: Baseline up to Study Week 64

    Proportion of subjects with at least one asthma exacerbation as recorded by the investigator in the Case Report Form(CRF). This is presented as proportion of subjects with at least one asthma exacerbation.

  10. Incidence and severity of adverse events (AE)

    Time frame: Baseline up to Study Week 64

    The incidence of adverse events in subjects recorded by the investigator in CRF.

    The evaluation criteria for the severity of adverse events were carried out in accordance with [NCI- CTCv5.0].

  11. Mean Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) (Weekly Means).

    Time frame: Baseline up to Study Week 64

    Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

  12. Mean Change From Baseline in Night Time Awakenings (Weekly Means)

    Time frame: Baseline up to Study Week 64

    Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.

  13. Change From Baseline in Blood Eosinophils .

    Time frame: Baseline up to Study Week 64

    Mean change from baseline in Blood Eosinophils measured at site

  14. Change From Baseline in Total Serum immunoglobulin E(IgE).

    Time frame: Baseline up to Study Week 64

    Mean change from baseline in Total Serum IgE measured at site

  15. Incidence and severity of serious adverse events (SAE)

    Time frame: Baseline up to Study Week 64

    The incidence of serious adverse events in subjects recorded by the investigator in CRF.

    The evaluation criteria for the severity of serious adverse events were carried out in accordance with [NCI-CTCv5.0].

  16. abnormal laboratory test indicators

    Time frame: Baseline up to Study Week 64

    Researchers make medical judgment according to the severity of abnormal indicators and the relevant conditions of patients' diseases.

Sponsors and collaborators

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Industry

Registry information

Official study title

A Multicenter,Randomized,Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Poorly Controlled Severe Asthma

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jul 25, 2022
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.